Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.

Stephanie L. Wethington,Payal D. Shah,Lainie P. Martin,Janos L. Tanyi,Nawar A. Latif,Mark A. Morgan,Drew A. Torigian,Cheyenne Pagan,Diego Rodriguez,Susan M. Domchek,Ronny Drapkin,Ie Ming Shih,Simon Smith,Emma Dean,Deborah K. Armstrong,Stephanie Gaillard,Fiona Simpkins

Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.

2021

Stephanie L. Wethington
Payal D. Shah
Lainie P. Martin
Janos L. Tanyi
Nawar A. Latif
Mark A. Morgan
Drew A. Torigian
Cheyenne Pagan
Diego Rodriguez
Susan M. Domchek
Ronny Drapkin
Ie Ming Shih
Simon Smith
Emma Dean
Deborah K. Armstrong
Stephanie Gaillard
Fiona Simpkins

5516Background: Following multiple blockbuster studies demonstrating long-term progression free and overall survival benefits with poly(ADP-ribose)polymerase inhibitors (PARPi), they have become an...

Keywords:

Cancer research
Polymerase
Medicine
overall survival
Recurrent Ovarian Cancer
Poly ADP ribose polymerase
PARP inhibitor
Olaparib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations